Physician profile
Melissa E Krisht
NPI 1316467616
$1,578.19
in general payments reported to CMS, 2019-2025
18 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $344 · 2022: $543 · 2023: $269 · 2024: $94.78 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $586.20 | 2021-2025 | |
| Gilead Sciences, INC. | $201.91 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.34 | 2021-2023 | Plenvu, Xifaxan |
| Janssen Biotech, INC. | $108.98 | 2021-2023 | Stelara |
| E.R. Squibb & Sons, L.L.C. | $96.66 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $90.75 | 2025 | Fanapt |
| Nestle Healthcare Nutrition INC. | $55.92 | 2021 | |
| Medtronic, INC. | $47.50 | 2021-2022 | |
| Boston Scientific Corporation | $46.89 | 2021-2022 | |
| Redhill Biopharma INC. | $39.77 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.35 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $23.43 | 2025 | Rexulti |
| Qol Medical, LLC | $19.66 | 2023 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $19.43 | 2025 | Trintellix |
| Neurocrine Biosciences, INC. | $18.91 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $15.51 | 2022 | |
| Braintree Laboratories, INC. | $14.68 | 2023 | Sutab |
| Celgene Corporation | $12.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Krisht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.